Gubra – Presentation of Phase 1 Topline Results on ABBV-295 long-acting amylin analog

You can already now sign up for the event and submit your questions. You don’t have to participate live to submit questions for the event.

On the 9th of March AbbVie reported positive topline results from the multiple ascending dose (MAD) portion of the Phase 1 trial for ABBV-295, Gubra’s out-licensed long-acting amylin analog.

In connection with these data, we will host a live event on the 10th of March with CFO Kristian Borbos and IR and Strategy Lead Emma Jappe Lange from Gubra, who will present the data and the findings from the study. After the presentation, there will be a Q&A session.

The study demonstrated dose-dependent weight loss ranging from -7.75% to -9.79% at week 12 for the weekly dosing cohorts, and -7.86% to -9.73% at week 13 for the less frequent dosing regimens (every other week and monthly after week 5), compared to approximately -0.25% for placebo.

Importantly, ABBV-295 was well tolerated at all dose levels, with no serious adverse events reported and gastrointestinal side effects that were mostly mild and concentrated in the first six weeks of treatment. The data support continued development of ABBV-295 as a differentiated, non-incretin obesity treatment.

It is also important to highlight the data related to one of the main selling points for ABBV-295: its long half-life. The every-other-week and monthly dosing cohorts showed efficacy comparable to the weekly dosing cohorts, potentially enabling less frequent dosing as a key differentiator.

Disclaimer: HC Andersen Capital receives payment from Gubra for a Digital IR/Corporate Visibility subscription agreement. Michael Friis at 15.48 PM, d. 09-03-2026.